Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUMO1 pseudogene 4 (SUMO1P4) is a noncoding genomic sequence classified as a pseudogene of the Small ubiquitin-related modifier 1 (SUMO1) gene[5]. Unlike protein-coding paralogues such as SUMO1—which is involved in post-translational modification (sumoylation) with roles in nuclear transport, transcription regulation, apoptosis, and protein stability—SUMO1P4 does not produce a functional protein and is typically considered biologically inactive[1][5][4]. Pseudogenes like SUMO1P4 may be retained in genomes as remnants of evolutionary processes and, while some pseudogenes can exert regulatory effects in rare cases, no such function has been established for SUMO1P4[4]. Key point: SUMO1P4 is not a therapeutic target, enzyme, receptor, or transporter, but a pseudogene with no known biological functions or disease roles, and is not relevant for drug discovery or clinical applications. If your intention was to investigate SUMO1 (Small ubiquitin-like modifier 1), that is a protein-coding gene and a legitimate target involved in sumoylation-related pathways and disease, but SUMO1P4 itself is not[1][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUMO1 pseudogene 4 (SUMO1P4).